Description
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL)
Location: CPMC (San Francisco)
Please Contact mailto:clinicalresearch@sutterhealth.org for more information about Nektar PROPEL
View study details on ClinicalTrials.gov
Principal Investigator
Co-Investigator(s)
Recruitment Status
Active, Not Recruiting
Start Date
February 01, 2019